Survival after surgery for intermediate and late stage kidney cancer varies from person to person. Some studies say that the 5-year survival rate of its intermediate stage patients is about 60% and the 10-year survival rate is about 20%, while it is worse in late stage. Kidney cancer is a collective term for malignant tumors occurring in the kidney, including primary kidney cancer and secondary kidney cancer, primary kidney cancer is the most common, and clear cell carcinoma accounts for about most of them. Its treatment mainly consists of surgical resection, and for middle and late stage patients, they need to receive adjuvant therapy (e.g. targeted therapy, etc.) after surgical treatment. The prognosis of renal cancer is related to pathological subtype, disease stage (size, metastasis, etc.), patient’s own condition and treatment effect. Intermediate-stage patients are mainly treated with radical surgery, and need to receive targeted therapy, immunotherapy and other auxiliary means after surgery. Patients with advanced stage usually lose the chance of surgery, and comprehensive treatment is the mainstay. According to a domestic study, after radical surgery for intermediate-stage renal cancer, 71.2% of patients developed distant metastasis within 5 years; the 3- and 5-year tumor-specific survival rates were 76.0% and 58.3%, respectively; and according to another study, the 5-year survival rate of intermediate-stage patients was about 60%, and the 10-year survival rate was about 20%. The prognosis of patients with advanced stage is even worse. In conclusion, there are many factors affecting the survival of kidney cancer patients, so it is recommended to go to regular hospitals to evaluate the condition and follow the doctor’s instructions to cooperate with the treatment, so as to avoid delaying the condition.